Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Dec 20;136(24):3019-3021.
doi: 10.1097/CM9.0000000000002550. Epub 2023 Aug 30.

Transcriptome dysregulation in hyper-progressive disease samples with immune checkpoint blockade

Dan Xue  1   2 , Tengteng Zhu  3 , Hongguang Lin  1   2 , Peilin Guo  1 , Mengling Li  1 , Mei'e Yu  1 , Fan Yang  1 , Sheng Yang  4 , Xiangqi Chen  1   2   5
Affiliations

Transcriptome dysregulation in hyper-progressive disease samples with immune checkpoint blockade

Dan Xue et al. Chin Med J (Engl). .
No abstract available

PubMed Disclaimer

Conflict of interest statement

None.

Figures

Figure 1
Figure 1
(A) Comparison of immune cell score in HPD and ICB drug responding (DR) and non-responding non-HPD samples (NR); (B) HPD upregulated genes (orange-colored) and unchanged genes (green-colored) in the antigen processing and presentation pathways, hsa 04612; (C) gene pathway enrichment of differentially spliced genes for HPD compared with ICB response genes; (D) overexpression of SRSF2 in A549 and H1650 cell lines. Left: The fold change of the relative invasion. *P <0.05, †P <0.01 vs. control. Right: Representative images of invasion ability test examined by transwell invasion assay. Scale bar was 50 μm in HE staining. CIIV: Class II vesicles; E.R.: Endoplasmic reticulum; HE: Hematoxylin-eosin; HPD: Hyper-progressive disease; ICB: Immune checkpoint blockade; MHC: Major histocompatibility complex; MIIC: Minnesota Immunization Information Connection; NC: Control cell line; NK: Natural killer.
See this image and copyright information in PMC

References

    1. Kamada T Togashi Y Tay C Ha D Sasaki A Nakamura Y, et al. . PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer. Proc Natl Acad Sci U S A 2019; 116: 9999–10008. doi: 10.1073/pnas.1822001116. - PMC - PubMed
    1. Ferrara R Mezquita L Texier M Lahmar J Audigier-Valette C Tessonnier L, et al. . Hyperprogressive disease in patients with advanced non-small cell lung cancer treated with PD-1/PD-L1 inhibitors or with single-agent chemotherapy. JAMA Oncol 2018; 4: 1543–1552. doi: 10.1001/jamaoncol.2018.3676. - PMC - PubMed
    1. Cho JW Hong MH Ha SJ Kim YJ Cho BC Lee I, et al. . Genome-wide identification of differentially methylated promoters and enhancers associated with response to anti-PD-1 therapy in non-small cell lung cancer. Exp Mol Med 2020;52: 1550–1563. doi: 10.1038/s12276-020-00493-8. - PMC - PubMed
    1. Armstrong TD, Clements VK, Martin BK, Ting JP, Ostrand-Rosenberg S. Major histocompatibility complex class II-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunity. Proc Natl Acad Sci U S A 1997;94: 6886–6891. doi: 10.1073/pnas.94.13.6886. - PMC - PubMed
    1. Alspach E Lussier DM Miceli AP Kizhvatov I DuPage M Luoma AM, et al. . MHC-II neoantigens shape tumour immunity and response to immunotherapy. Nature 2019;574: 696–701. doi: 10.1038/s41586-019-1671-8. - PMC - PubMed

Publication types

Substances

Associated data